Merck
In Brief This Week: Mount Sinai, AAVantgarde Bio, Lantern Pharma, Exegenesis Bio, AlveoGene
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Merck, Moderna Vax Trial Starts Enrolling Lung Cancer Patients at McGill University Health Center
The trials are evaluating an individualized neoantigen vaccine with Keytruda as an adjuvant therapy for non-small cell lung cancer.
Merck Talks Up Pipeline Diversification as Keytruda Sales Still Comprise 45 Percent of Q3 Revenues
Premium
The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in the third quarter.
Akeso Begins Phase III Study of Anti-PD-1 Combo in Head and Neck Cancer
The firm is pitting a combination therapy targeting PD-1, VEGF, and CD47 against Keytruda in first-line advanced head and neck cancer.
Merck, Moderna Launch Phase III Trial of Adjuvant V940 in NSCLC After Neoadjuvant Keytruda, Chemo
The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.